伊人久久大香线蕉AV影院,情侣国产一二三区视频观看,香蕉丝瓜榴莲在线观看√天堂资源中文官网,日韩精品无码观看视频免费,亚洲伊人成无码综合网欧美亚洲综合在线一区,国产午夜精品视频一区二区三区,亚洲毛片在线日韩无码大乱交,国产精品国产三级欧美二区

Mabwell Announces the First Patient Dosed in the Clinical Studies of 2 Novel ADCs

Release time:Sep 05, 2023

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that the first patient dosed in the Phase I/II studies for Trop-2 targeting ADC (R&D code: 9MW2921) and B7-H3 targeting ADC (R&D code: 7MW3711), respectively.

The primary objective of Phase I/II study of 9MW2921 (Register No.: CTR20232341) is to investigate the safety and tolerability, explore the maximum tolerated dose (MTD), confirm the RP2D, and preliminarily evaluate the efficacy of 7MW3711 in particular tumor types.

The primary objective of phase I/II study of 7MW3711 (Register No.: CTR20232441) is to investigate the safety, tolerability, MTD and/or RP2D, and preliminarily evaluate the efficacy of 7MW3711 in particular tumor types.

 

Trop-2 targeting ADC (9MW2921)

9MW2921 is a next generation antibody-drug conjugate (ADC) developed by Mabwell based on IDDC? platform for the treatment of solid tumors. It is an innovative antibody molecule linked to a novel payload (TOP1i) by a novel linker with fully autonomous intellectual property right. When 9MW2921 enters the body, it can specifically bind to antigens on the cell membrane surface, be internalized and trafficked to the lysosome, release cytotoxic drug, and induce the apoptosis of tumor cells.

9MW2921 is pharmaceutical characterized as stable structure, homogeneous composition, high purity, and it is suitable for industrial scale-up. Compared with ADCs of the same class under development at home and abroad, 9MW2921 is significantly improved and optimized in endocytic activity, plasma stability, drug release characteristics, bystander killing effect, etc. In vivo pharmacodynamic studies demonstrated that 9MW2921 had a better tumor killing activity. In animal safety evaluation models including cynomolgus monkeys and rats, the on-target and off-target toxicities of 9MW2921 were effectively controlled, indicating that 9MW2921 has good safety profile and pharmacokinetic properties.


B7-H3 targeting ADC (7MW3711)

The next generation antibody-drug conjugate molecule 7MW3711 with proprietary intellectual property right, developed by Mabwell's next-generation antibody-drug conjugate platform IDDC?, is composed of innovative antibody molecule, novel linker, and novel payload (TOP1i). When 7MW3711 enters human body, it specifically binds to antigens on the tumor cell membrane surface, be internalized and trafficked to the lysosome, release cytotoxic drug, and induce the apoptosis of tumor cells.

7MW3711 is pharmaceutical characterized as stable structure, homogeneous composition, high purity, and it is suitable for industrial scale-up. Compared with drugs in the same class at home and abroad, 7MW3711 has shown better tumor killing effects in multiple animal tumor models. In the safety evaluation model of animals including cynomolgus monkeys, the on-target and off-target toxicities of 7MW3711 are effectively controlled, showing its good safety profile and pharmacokinetic properties. The above research results indicate that 7MW3711 has clinical differentiation characteristics and a promising future of clinical development.

 

Next generation antibody-drug conjugate platform IDDC?

Mabwell has developed multiple ADC technology platforms, and its Nectin-4-targeting ADC (R&D code: 9MW2821) is currently in the phase II study.

IDDC? is a next generation ADC site-specific conjugate technology platform independently developed by Mabwell. It is composed of multiple systematized core patent technologies including site-specific conjugate process DARfinity?, special designed linker IDconnect?, novel payload Mtoxin?, and conditional release structure LysOnly?, which improves structural homogeneity, quality stability, pharmacodynamics and tolerability of the ADC products.

Currently, the advantage of the IDDC? platform has been validated in several products under development. Trop-2-targeting ADC (R&D code: 9MW2921) has been approved for clinical study in advanced solid tumor. It is expected multiple ADC products will enter clinical development in 2023 and 2024.

国产精品午夜无码AV体验区| 日本护士野外XXXHD| 日韩在线视精品中文字幕在线播放| 欧美成人精品动漫在线专区| 377人体粉嫩噜噜噜| 在线亚洲+欧美+日本专区| 久久99国产精一区二区三区| 日韩欧美国产亚洲另类| 国产色青青视频在线观看撒| 亚洲欧美另类精品在线观看| 一级成人a毛片免费播放 | 精品一卡2卡三卡4卡乱码精品视频| 日韩精品一区二区三区九九| 开心婷婷五月激情综合社区| 国色天香社区视频手机版| 欧美级婬片A片免费播放口r| 亚洲成A人片在线观看日本| 精品成在人线av无码免费看| 国产免费人成视频在线观看| 波多野结衣一区二区免费视频| 亚洲国产日韩欧美综合久久| 国产精品午夜爆乳美女视频| 国产精品初高中害羞小美女| 国产美女 91 在线播放 | 99久久精品无码一区二区毛片免费| 国产又粗又黄又猛又爽| 国产福利一区二区三区高清| 中国一级毛片在线观看| 亚洲男同帅GAY片在线观看| 久久久久久久久久国产精品免费| 久久精品成人无码AV片观看| 日本xxxx高清色视频在线播放| 少妇久久久久久人妻无码| 中国少妇×xxxx性裸交| 久久久亚洲精品动漫无码| 日韩在线观看高清视频| 动漫精品一区二区三区在线观看 | 精品久久久噜噜噜久久久| 亚洲日本中文字幕天天更新| AWWW在线天堂BD资源在线| 国产精品亚洲αv天堂无码|